EyePoint Pharmaceuticals : EYPT Investor Presentation December 2023

Investor Presentation

December 2023

©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Legal Disclaimers

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources through topline data for the Phase 3 DAVIO 3 clinical trials; our expectations regarding the timing and clinical development of our product candidates, including EYP-1901 and EYP-2301; the potential for EYP- 1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

2 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Committed to

developing

therapeutics to

improve the lives of patients with serious retinal diseases

3 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

Pipeline represents multi billion-dollar opportunities using our bioerodible Durasert E™ IVT delivery technology

• EYP-1901 - vorolanib, a selective and patented TKI
• • Positive topline Phase 2 data in wet AMD
  • Phase 3 trials in wet AMD planned to initiate in 2H 2024
  • Topline Phase 2 data in NPDR anticipated in Q2 2024
  • Phase 2 trial in DME planned to commence in Q1 2024
• EYP-2301- razuprotafib, a patented TIE-2 agonist for serious retinal diseases

Durasert® - proven, safe IVT drug delivery technology

• Routine in-office IVT injection
• Bioerodible Durasert E™ and non-erodible formulations
• Safely administered to thousands of patient eyes across four FDA approved products with non-erodible formulations

Strong Balance Sheet

• $136.0M of cash and investments on September 30, 2023
• $230.0M equity financing completed December 5, 2023
• Cash runway through topline data for Phase 3 wet AMD pivotal trials

IVT, intravitreal injection

Pipeline Represents Multibillion Dollar Product Opportunities

Durasert E™ Programs	Indication	Discovery	Pre-Clin	Phase 1	Phase 2	Phase 3	Next Milestone
		single-dose,6-month maintenance therapy		EOP2 Mtg with
	Wet AMD	160 patients complete with positive Phase 2 topline data		FDA, Phase 3
							initiation in 2H 2024
EYP-1901 - vorolanib		single-dose,9-month treatment			Topline data in
(tyrosine kinase inhibitor)	NPDR
	77 patients			Q2 2024
	DME	single-dose,6-month treatment			Trial initiation in
			Q1 2024
EYP-2301 - razuprotafib	serious retinal						Pre-clin tox and PK
(TIE-2 agonist)	diseases						data in 2024
Complement inhibition	GA						Potential product
					candidate in 2024

	non-clinical	trial planned	trial underway
4	©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	wet AMD, wet age-related macular degeneration; EOP2, End of Phase 2; FPI, first
patient in; NPDR, non-proliferative diabetic retinopathy; DME, diabetic macular edema;

GA, geographic atrophy

Vorolanib Brings a Potential New MOA to the Treatment of VEGF- Mediated Retinal Diseases by Blocking all Isoforms of VEFG and PDGF

• Potent and selective pan-VEGF receptor inhibition
• Composition of matter patent into

2037 (potential patent term extension to 2042)

• Demonstrated neuroprotection in a validated retinal detachment animal model
• Blocks PDGF which may lead to antifibrotic benefit
• Reduced off-target binding and does not inhibit TIE-2 at clinically relevant doses

		SoC, standard of care; ANG, angiopoietin; PDGF(R), platelet-derived growth factor
5	©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	(receptor); PLGF, placental growth factor; TIE-2,tyrosine-protein kinase receptor
		TIE-2; VEGF(R), vascular endothelial growth factor (receptor).

TECHNOLOGY

DURASERT®

Safe Sustained IVT Drug Delivery

• Delivered by a single in-office IVT injection
• Continuous, stable release of drug
• Zero-orderkinetics

Durasert E™: bioerodible

• Insert consists of drug embedded within a bioerodible matrix
• Designed to deplete drug load before matrix fully erodes

Durasert®: non-erodible

• Drug embedded within a bioerodible matrix coated with non-erodible polyimide shell:
• • YUTIQ®1
  • ILUVIEN®1
  • RETISERT®2
  • VITRASERT®2

©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

6

1- licensed to Alimera; 2 - licensed to Bausch and Lomb

EYP-1901: Receptor Binding Vorolanib In Bioerodible Durasert E™

Each insert ~1/5000 of vitreous volume

• Delivered in the physician office via standard intravitreal injection
• Immediately bioavailable featuring an initial burst of drug followed by zero order kinetics release for ~9 months
• Positive safety and efficacy data in wet AMD from Phase 1 DAVIO clinical trial
• Continued positive safety data in ongoing Phase 2 clinical trials with all patients at least six months post injection
• Shipped and stored at ambient temperature

7

©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

IVEGF - vascular endothelial growth factor: AMD - age related macular degeneration;

EYP-1901

PHASE 1 DAVIO CLINICAL TRIAL IN WET AMD RESULTS

©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

DAVIO Phase 1 Clinical Trial in Wet AMD - Overview

• Multicenter, open-label,single-injectiondose-escalation trial (4 doses)
• Previously treated patients only (8.6 mean injections in previous 12 months)
• Fluid status at entry was not an exclusion criterion - all comers
• Minimum of three anti-VEGF injections in 6 months​ prior to enrollment
• Single IVT of aflibercept followed by single EYP-1901 dose (~1 week later)
• Primary endpoint: Safety (ocular & non-ocular TEAEs through month 12​)
• Secondary endpoints: Change in BCVA & CST​; supplemental anti-VEGF injections

9	©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.	TEAE, treatment emergent adverse events; BCVA, best corrected visual acuity;
CST, central subfield thickness; IVT- intravitreal

EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives And Informed Phase 2 Design

FAVORABLE SAFETY PROFI LE

• No ocular SAEs reported
• No drug-related systemic SAEs reported
• Ocular AEs - majority were mild and expected with IVT administration

POSI TIVE EFFI CACY & DURABI LITY

Endpoint	DAVIO	DAVIO Subgroup
(6-month)	Analysis*
Change in BCVA	-2.5	-0.4
Reduction in	75%	92%
Treatment Burden
Percent of Eyes	53%	67%
Supplement-Free
OCT	-3.4 µm	-1.0 µm

10

©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

*Retrospective analysis of nine subjects with no excess fluid at screening